Under-the-skin injection of Tysabri gets licence in UK and Ireland
16 April 2021
Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.
Ofatumumab (Kesimpta) gets UK licence for relapsing remitting MS
14 April 2021
The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.
How long does it take for an MS drug to be fully effective?
31 March 2021
Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.
Do medicines reduce fatigue in MS?
8 March 2021
This study compared the effectiveness of amantadine, modafinil and methylphenidate with placebo in people with MS-related fatigue.
Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 February 2021
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Exercise is good for your brain
3 February 2021
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.
Covid-19 vaccines and MS: Part two
29 January 2021
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.
Ozanimod (Zeposia) for relapsing remitting multiple sclerosis rejected by NICE
22 January 2021
The MS Trust is very disappointed that NICE does not recommend ozanimod (Zeposia) as an NHS treatment in England and Wales.
Researchers develop mRNA vaccine to treat MS-like condition in mice
14 January 2021
A potential treatment for multiple sclerosis uses mRNA technology, similar to two of the Covid-19 vaccines. Find out more about this research.
Daytime sleepiness and driving in MS
6 January 2021
In this study, researchers compared daytime sleepiness while driving in people with and without MS.
Remyelination research: what it means for people with MS
22 December 2020
Most people with MS will have heard of demyelination but perhaps not remyelination. We spoke with Dr Nick Cunniffe, who has been involved in some of the recent remyelination research, to find out more.
Covid-19 vaccine and MS: Your questions answered
8 December 2020
There's been a lot of interest around the new Covid-19 vaccines and how they might affect people with multiple sclerosis (MS). We've collected some common questions and answers from the MS Trust Enquiry Service this week to share with you.